SELUTION 4 De Novo 小型容器 IDE 试用
一项前瞻性随机单盲多中心研究,旨在评估 SELUTION SLR™ 014 PTCA 药物洗脱球囊治疗小血管新发冠状动脉病变受试者的安全性和有效性
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA.
The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a parallel pharmacokinetic (pK) substudy, at up to 80 sites in the US, Canada, Brazil, Japan and Europe. A minimum of 50% of the subjects will be enrolled in the US.
研究概览
详细说明
Prospective, randomized controlled, single-blind, multicenter, clinical trial
The study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a parallel pharmacokinetic (pK) substudy, at up to 80 sites in the US, Canada, Brazil, Japan and Europe. A minimum of 50% of the subjects will be enrolled in the US.
Subjects who present with chronic coronary syndrome (CCS), unstable angina or stabilized non-ST elevation myocardial infarction (NSTEMI) with an indication for percutaneous coronary intervention (PCI) with planned intervention for de novo lesions in small coronary vessels (RVD 2.00 mm to 2.75 mm) and meeting all eligibility criteria will be randomized 1:1 to treatment of the identified target lesion with either the SELUTION SLR 014 PTCA DEB or contemporary DES.
Randomized Cohort:
- Intervention (DEB Strategy): Subjects randomized to the SELUTION SLR 014 PTCA DEB arm will receive lesion preparation according to the 3rd drug coated balloon (DCB) consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, intravascular lithotripsy, laser, rotational or orbital atherectomy, cutting or scoring balloon at the discretion of the operator as needed to reduce diameter stenosis to ≤ 30%). Subjects with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis > 30%) will receive a DES instead of the SELUTION DEB but remain in the SELUTION DEB group (intention to treat analysis). The DEB should not be used after DES implant.
- Control (DES): Subjects randomized to the DES arm will receive treatment using any FDA approved "limus-based" DES, as per standard institutional practice.
Angiographic Substudy:
The angiographic substudy is a parallel registry consisting of up to 30 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. These subjects will undergo angiography at 12 months post-procedure. Clinical follow-up will not extend beyond 12 months in this cohort.
Pharmacokinetic (pK) Substudy:
The pKsubstudy is a parallel registry consisting of up to 20 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. This study will be conducted under an approved substudy protocol and will include blood draws at regular intervals to characterize the pK plasma profile of sirolimus.
Primary Endpoint:
Target lesion failure (TLF), defined as the composite of cardiac death, target-vessel myocardial infarction (MI) or clinically-driven target lesion revascularization (TLR) at 12 months. MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Bad Krozingen、德国、79189
- Universitäts-Herzzentrum Freiburg
-
Berlin、德国、12683
- UKB Berlin
-
Dresden、德国、01307
- Herzzentrum Dresden
-
-
-
-
-
Genk、比利时、3600
- ZOL Genk
-
Hasselt、比利时、3500
- Hartcentrum Hasselt Jessa Ziekenhuis
-
-
-
-
Arkansas
-
Jonesboro、Arkansas、美国、72401
- St. Bernards
-
-
California
-
Chula Vista、California、美国、91911
- CISD Sharp Chula Vista
-
Los Angeles、California、美国、90048
- Cedars Sinai
-
Thousand Oaks、California、美国、91360
- HCA Los Robles
-
Torrance、California、美国、90502
- Harbor UCLA
-
-
Colorado
-
Golden、Colorado、美国、80401
- Colorado Heart and Vascular
-
Thornton、Colorado、美国、80023
- ClinRe
-
-
Connecticut
-
New Haven、Connecticut、美国、06520
- Yale New Haven Hospital
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- MedStar Washington Hospital Center
-
-
Florida
-
Bradenton、Florida、美国、34208
- Manatee Memorial
-
Clearwater、Florida、美国、34695
- Mease Countryside Hospital
-
Jacksonville、Florida、美国、32209
- University of Florida, Jacksonville
-
Largo、Florida、美国、33770
- HCA Largo
-
Orlando、Florida、美国、32803
- AdventHealth Orlando
-
St. Petersburg、Florida、美国、33709
- HCA Northside
-
Trinity、Florida、美国、34655
- HCA Trinity
-
-
Georgia
-
Atlanta、Georgia、美国、30309
- Piedmont Heart Institute
-
Atlanta、Georgia、美国、30033
- Atlanta VA
-
Atlanta、Georgia、美国、30322
- Emory
-
Dalton、Georgia、美国、30720
- Hamilton Medical Center
-
Thomasville、Georgia、美国、31792
- Archbold Memorial Hospital
-
-
Hawaii
-
‘Aiea、Hawaii、美国、96701
- Pali Momi Medical Center
-
-
Illinois
-
Downers Grove、Illinois、美国、60515
- Advocate Good Samaritan Hospital
-
Oak Lawn、Illinois、美国、60453
- Advocate Christ Medical Center
-
Urbana、Illinois、美国、61801
- Carle Foundation Hospital
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- University of Iowa Medical Center
-
-
Kansas
-
Wichita、Kansas、美国、67226
- Cardiovascular Research Institute of Kansas
-
-
Kentucky
-
Lexington、Kentucky、美国、40503
- Baptist Health Lexington
-
-
Louisiana
-
Houma、Louisiana、美国、70360
- Cardiovascular Institute of the South
-
-
Maryland
-
Baltimore、Maryland、美国、21201
- University of Maryland
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- Brigham & Women's
-
Boston、Massachusetts、美国、02114
- Mass General
-
Boston、Massachusetts、美国、02114
- Beth Israel Deaconess
-
Springfield、Massachusetts、美国、01199
- Baystate Medical Center
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55417
- Minneapolis VA Medical Center
-
Minneapolis、Minnesota、美国、55407
- Minneapolis Heart Institute
-
-
Mississippi
-
Tupelo、Mississippi、美国、38801
- North Mississippi Medical Center
-
-
Missouri
-
Overland Park、Missouri、美国、66211
- HCA Overland Park
-
St Louis、Missouri、美国、63136
- St. Louis Heart and Vascular
-
-
Nebraska
-
Omaha、Nebraska、美国、68198
- University of Nebraska
-
-
New Jersey
-
Englewood、New Jersey、美国、07631
- Englewood Health
-
-
New York
-
New York、New York、美国、10029
- Icahn School of Medicine at Mount Sinai
-
New York、New York、美国、10075
- Northwell Health Lenox Hill
-
Stony Brook、New York、美国、11794
- Stony Brook University Hospital
-
-
North Carolina
-
Raleigh、North Carolina、美国、27607
- NC Heart and Vascular
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- The Lindner Research Center at Christ
-
Cleveland、Ohio、美国、44120
- UH Cleveland
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73120
- Oklahoma Heart
-
-
Pennsylvania
-
Hershey、Pennsylvania、美国、17033
- Penn State Health Hershey & Berks
-
Mechanicsburg、Pennsylvania、美国、17050
- UPMC Pinnacle
-
York、Pennsylvania、美国、17403
- WellSpan York Hospital
-
-
Rhode Island
-
Providence、Rhode Island、美国、02903
- Lifespan Rhode Island & Miriam
-
-
Tennessee
-
Chattanooga、Tennessee、美国、37404
- CHI Memorial
-
Chattanooga、Tennessee、美国、37404
- University of Nebraska
-
Nashville、Tennessee、美国、37203
- HCA Centennial
-
-
Texas
-
Abilene、Texas、美国、79601
- Hendrick Health
-
Dallas、Texas、美国、75231
- Texas Health
-
Dallas、Texas、美国、75246
- Baylor Scott and White - Dallas
-
Fort Worth、Texas、美国、76104
- Medical City of Fort Worth
-
Plano、Texas、美国、75093
- Baylor Scott and White Plano
-
Temple、Texas、美国、76508
- Baylor Scott and White - Temple
-
-
Utah
-
Murray、Utah、美国、84107
- Intermountain Health - Salt Lake City
-
-
Virginia
-
Richmond、Virginia、美国、23225
- HCA Chippenham
-
-
West Virginia
-
Charleston、West Virginia、美国、25304
- CAMC
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53215
- Advocate Aurora St. Luke's
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Clinical Inclusion Criteria
Subjects must meet all of the following clinical criteria to participate in the trial:
- Subject is ≥ 18 years (or the minimum legal age as required by local regulations).
- Female subjects of childbearing potential must have a negative pregnancy test ≤ 7 days before the procedure or are using a contraceptive device or drug.
- Subject presents with chronic coronary syndromes [CCS] (manifest as documented angina or positive functional testing), unstable angina or stabilized non-ST elevation myocardial infarction (NSTEMI) (biomarkers stabilized or down trending) with an indication for PCI and planned intervention.
- Subject can tolerate dual antiplatelet therapy with aspirin, plus either Clopidogrel, Prasugrel, or Ticagrelor. (Note: For subjects requiring oral anticoagulation, aspirin may be omitted based on investigator discretion).
- Subject has life expectancy > 1 year in the opinion of the investigator.
- Subject is willing and able to provide informed consent and comply with study procedures and required follow-up evaluations.
PK Sub- Study Inclusion Criteria:
Subjects must meet all of the main protocol inclusion criteria to participate in the PK sub-study. Subjects must also meet the following additional PK sub-study inclusion criteria:
1. Subject is willing and able to provide informed consent for the PK sub-study and comply with the PK sub-study procedures and required follow-up evaluations.
Imaging Inclusion Criteria
Subject's target lesion(s) must meet all of the following angiographic criteria for the subject to participate in the trial:
- A single, target lesions that meet criteria can be treated in a single vessel. No non-target lesions can be treated within the target vessel in the index procedure. Non-target lesions within the target vessel can be staged for treatment > 30 days from the index procedure.
- Up to two (2) non-target lesions in up to two (2) non-target vessels may be treated, but successful PCI of the non-target lesions must be completed before randomization and treatment of the target lesion.
- Target lesion is ≤ 36 mm in length.
- Target lesion has diameter stenosis > 50% and ≤ 99% with distal flow at least thrombolysis in myocardial infarction (TIMI) 2.
- Target vessel has RVD of ≥ 2.00 mm and ≤ 2.75 mm [by visual assessment].
- Target lesion is within a native coronary artery or major branch.
- A target lesion within a bifurcation is allowed only if a single vessel (either main vessel or side branch) is to be treated.
- The identified target lesion has high probability for successful treatment with approved pre-treatment techniques and DEB alone based on Investigator assessment.
Exclusion Criteria:
- Clinical Exclusion Criteria
Subjects who meet any of the following clinical criteria will be excluded from the trial:
- Subject with known hypersensitivity or allergy to Sirolimus or its analogues.
- Subject presents with NSTEMI and rising biomarkers, or ongoing chest pain or is hemodynamically instable.
- Subject with history of ST-elevation myocardial infarction (STEMI) within 30 days of the index procedure.
- Subject with planned major surgery within 30 days following the index procedure.
- Subject with planned treatment of lesion involving aorto-ostial location.
- Subject with PCI of a non-target vessel within ± 30 days of the index procedure.
- Subject with history (within 6 months prior to index procedure) of New York Heart Association (NYHA) class III or IV heart failure.
- Subject with history of active peptic ulcer or gastrointestinal bleeding within 6 months of the index procedure or other inability to comply with the recommended duration of dual antiplatelet therapy (DAPT).
- Subject is pregnant, breast-feeding or a woman of childbearing potential who plans pregnancy up to 1 year following index procedure.
- Subjects with current documented left ventricular ejection fraction (LVEF) < 30%.
- Subject is considered not able to tolerate at least 30 seconds of coronary occlusion for the target lesion treated.
- Subjects is currently participating in another investigational drug or device study that has not completed primary endpoint follow-up.
- Subject with definite clinically active COVID-19 infection defined as a positive COVID test within 24 hours of index procedure.
- Subject has chronic renal insufficiency (dialysis dependent, or glomerular filtration rate [GFR] ≤ 30 ml/min/1.73 m2 within 30 days of index procedure) or had undergone renal transplantation.
PK Sub-Study Exclusion Criteria:
Subjects must meet none of the main protocol exclusion criteria to participate in the PK sub-study. Subjects will be excluded if any of the following additional PK sub-study exclusion criteria are met:
-
Any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device has been placed/used in any part of the body within 3 months prior to the index procedure including non-target lesion(s) treated during the index procedure.
-
Planned intervention with any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device anywhere in the body within 6 months after the index procedure. Note: staged procedures >30 days after index procedure (Exclusion #6 of the main protocol) are permitted only in the main protocol, and are not permitted in this PK sub-study.
-
The subject is taking or has taken within the last 3 months any limus family medication(s) for any reason.
-
Subject is concurrently enrolled in the main protocol angiographic registry.
-
Subjects who are taking strong CYP3A4 Inhibitors within 14 days before the index procedure or plan to take the strong inhibitors during the study period. Strong inhibitors include: cobicistat; ritonavir; indinavir and ritonavir; itraconazole; ketoconazole; lopinavir and ritonavir; paritaprevir and ritonavir and ombitasvir (and/or dasabuvir); posaconazole; saquinavir and ritonavir; tipranavir and ritonavir; elvitegravir and ritonavir; telithromycin; voriconazole; ceritinib; clarithromycin; idealalisib; nefazodone; nelfinavir.
-
Subjects who are taking strong CYP3A4 Inducers within 14 days before the index procedure or plan to take the strong inducers during the study period. Strong inducers include apalutamide; carbamazepine; enzalutamide; ivosidenib; lumacaftor and ivacaftor; mitotane; phenytoin; rifampin; St. John's wort.
- Angiographic Exclusion Criteria
Subject whose target lesion(s) meet any of the following angiographic criteria will be excluded from the trial:
- Target lesion is totally occluded or has evidence of thrombus.
- Target lesion is located in the left main or any arterial or venous graft.
- Target lesion is in a side branch that is "jailed" by a main vessel stent.
- In stent restenosis
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:SELUTION SLR 014 PTCA DEB
SELUTION Sustained Limus Release (SLR) 014 Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon (DEB) The SELUTION SLR 014 PTCA DEB is a minimally invasive, single use and sterile Sirolimus coated PTCA balloon catheter. The SELUTION SLR 014 PTCA DEB is available with balloon diameters from 2.0 to 3.0 mm and lengths of 15 to 40 mm for the purpose of the De Novo IDE trial |
After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds. |
|
有源比较器:Control Treatment
any FDA approved "limus-based" Drug Eluting Stent, as per standard institutional practice |
For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices. The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain < 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Target lesion failure (TLF)
大体时间:12 months
|
Target lesion failure (TLF) is defined as the composite of cardiac death, target-vessel myocardial infarction (MI) or clinically-driven target lesion revascularization (TLR) at 12 months. MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition. |
12 months
|
|
PK Sub-study Primary Endpoint 1
大体时间:6 months
|
PK parameters of C(max) |
6 months
|
|
PK Sub-study Primary Endpoint 2
大体时间:6 months
|
PK parameters of T(max) |
6 months
|
|
PK Sub-study Primary Endpoint 3
大体时间:6 months
|
PK parameters of AUC(last) |
6 months
|
|
PK Sub-study Primary Endpoint 4
大体时间:6 months
|
PK parameters of MRT(last) |
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Secondary Endpoint 1
大体时间:12 months
|
Composite of all-cause mortality, target vessel MI or clinically driven target lesion revascularization |
12 months
|
|
Secondary Endpoint 2
大体时间:Up to 7 days
|
Lesion success, defined as attainment of < 30% residual stenosis of target lesion using any percutaneous method |
Up to 7 days
|
|
Secondary Endpoint 3
大体时间:Up to 7 days
|
Procedure success, defined as attainment of < 30% residual stenosis of the target lesion using the assigned study device only without the occurrence of in-hospital major adverse cardiac events (MACE), composite of all-cause death, MI or any clinically-driven TLR. |
Up to 7 days
|
|
Secondary Endpoint 4
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Composite safety endpoint, defined as the patient-oriented composite of any death, any MI (spontaneous or peri-procedural), or any repeat revascularization. |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 5
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
All-Cause Mortality |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 6
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Cardiovascular Mortality |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 7
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
MI (spontaneous MI using the 4th UDMI, peri-procedural MI using SCAI and Academic Research Consortium [ARC]-2 definitions) |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 8
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Clinically-driven TLR |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 9
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
all TLR |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 10
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Clinically-driven Target Vessel Revascularization (TVR) |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 11
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
all TVR |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 12
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Non-target lesion revascularization |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 13
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
TLF |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 14
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Target vessel failure (TVF), defined as a composite of: cardiac death, target vessel MI (spontaneous or peri-procedural) and any clinically-driven TVR |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 15
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Stent or target lesion segment thrombosis (definite or probable) according to the ARC criteria for acute, subacute, late, very late and cumulative stent thrombosis |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
|
Secondary Endpoint 16
大体时间:12 months
|
Bleeding Academic Research Consortium (BARC) class 2-5 |
12 months
|
|
Secondary Endpoint 17
大体时间:Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
Net adverse clinical events, defined as death, MI (spontaneous or peri-procedural), TVR, stent/target lesion segment thrombosis or bleeding (BARC types 2-5, assessed to 12 months) |
Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PK Sub-Study Secondary Endpoint 1
大体时间:6 months
|
If calculations are valid, additional PK parameter of AUC(inf). |
6 months
|
|
PK Sub-Study Secondary Endpoint 2
大体时间:6 months
|
If calculations are valid, additional PK parameter of Cl. |
6 months
|
|
PK Sub-Study Secondary Endpoint 3
大体时间:6 months
|
If calculations are valid, additional PK parameter of Vz. |
6 months
|
|
PK Sub-Study Secondary Endpoint 4
大体时间:6 months
|
If calculations are valid, additional PK parameter of Vss. |
6 months
|
|
PK Sub-Study Secondary Endpoint 5
大体时间:6 months
|
If calculations are valid, additional PK parameter of half-life. |
6 months
|
|
PK Sub-Study Secondary Endpoint 6
大体时间:6 months
|
Dose normalized C(max) will be considered if appropriate. |
6 months
|
|
PK Sub-Study Secondary Endpoint 7
大体时间:6 months
|
Dose normalized AUC will be considered if appropriate. |
6 months
|
|
PK Sub-Study Secondary Endpoint 8
大体时间:6 months
|
Device success, defined as attainment of ≤ 30% residual stenosis of the target lesion using the assigned device only |
6 months
|
合作者和调查者
调查人员
- 首席研究员:Ron Waksman, MD、Medstar Health Research Institute
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- SEL-003-2021
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.